Publications - Oncomedics

Publications Oncomedics

Chemotherapy outcome predictive effectiveness by the Oncogramme: pilot trial on stage-IV colorectal cancer. Bounaix Morand du Puch C, Nouaille M, Giraud S, Labrunie A, Luce S, Preux PM, Labrousse F, Gainant A, Tubiana-Mathieu N, Le Brun-Ly V, Valleix D, Guillaudeau A, Mesturoux L, Coulibaly B, Lautrette C, Mathonnet M. J Transl Med. 2016 Jan 12;14(1):10.
Sedimentation field flow fractionation monitoring of in vitro enrichment in cancer stem cells by specific serum-free culture medium. Mélin C, Perraud A, Bounaix Morand du Puch C, Loum E, Giraud S, Cardot P, Jauberteau MO, Lautrette C, Battu S, Mathonnet M. J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Jul 15;963:40-6.
Discrimination of colorectal cancer cell lines using microwave biosensors. Zhang LY, Bounaix Morand du Puch C, Dalmay C, Lacroix A, Landoulsi A, Leroy J, Mélin C, Lalloué F, Battu S, Lautrette C, Giraud S, Bessaudou A, Blondy P, Jauberteau MO, Pothier A. Sensors and Actuators A 216 (2014) 405–416.
Oncogramme, an Adapted Method for Individualized Tumour Response Testing of Ovary Cancer Treatments. Giraud S, Croce S, Bessette B, Stoeckle E, Guyon F, Mac Grogan G, Floquet A, Velasco V, Mannina C, Lautrette C. J Cancer Res Therap Oncol. 2014; 2: 1-9.
Improved sedimentation field-flow fractionation separation channel for concentrated cellular elution. Mélin C, Lacroix A, Lalloué F, Pothier A, Zhang LY, Perraud A, Dalmay C, Lautrette C, Jauberteau MO, Cardot P, Mathonnet M, Battu S. J Chromatogr A. 2013 Aug 9;1302:118-24.
Decrease in Fas-induced apoptosis by the γ-secretase inhibitor is dependent on p75(NTR) in a glioblastoma cell line. Bessette B, Durand K, Giraud S, Bégaud G, Mathonnet M, Lalloué F. Exp Ther Med. 2012 May;3(5):873-877.
Oncogramme responses of breast tumour cells treated with herceptin correlate with HER2/C-ERB B2 pathological status. Giraud S, Bounaix Morand du Puch C, Fermeaux V, Guillaudeau A, Lautrette C. Anticancer Res. 2012 Apr;32(4):1323-5.
P75 neurotrophin receptor is sequestered in the Golgi apparatus of the U-87 MG human glioblastoma cell line. Giraud S, Loum E, Bessette B, Mathonnet M, Lalloué F. Int J Oncol. 2011 Feb;38(2):391-9.
Oncogramme, a new promising method for individualized breast tumour response testing for cancer treatment. Giraud S, Loum E, Bessette B, Fermeaux V, Lautrette C. Anticancer Res. 2011 Jan;31(1):139-45.
Oncogramme, a new individualized tumor response testing method: application to colon cancer. Loum E, Giraud S, Bessette B, Battu S, Mathonnet M, Lautrette C. Cytotechnology. 2010 Oct;62(5):381-8.
In vitro apoptotic induction of human glioblastoma cells by Fas ligand plus etoposide and in vivo antitumour activity of combined drugs in xenografted nude rats. Giraud S, Bessette B, Boda C, Lalloué F, Petit D, Mathonnet M, Jauberteau MO. Int J Oncol. 2007 Jan;30(1):273-81
Increase of Fas-induced apoptosis by inhibition of extracellular phosphorylation of Fas receptor in Jurkat cell line. Lautrette C, Loum-Ribot E, Petit D, Vermot-Desroches C, Wijdenes J, Jauberteau MO. Apoptosis. 2006 Jul;11(7):1195-204.
Modulation of Fas-induced apoptosis by p75 neurotrophin receptor in a human neuroblastoma cell line. Giraud S, Lautrette C, Bessette B, Decourt C, Mathonnet M, Jauberteau MO. Apoptosis. 2005 Dec;10(6):1271-83.
Endothelial cell activation in the presence of African trypanosomes. Girard M, Giraud S, Courtioux B, Jauberteau-Marchan MO, Bouteille B. Mol Biochem Parasitol. 2005 Jan;139(1):41-9
Sedimentation field flow fractionation purification of immature neural cells from a human tumor neuroblastoma cell line. Lautrette C, Cardot PJ, Vermot-Desroches C, Wijdenes J, Jauberteau MO, Battu S. J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Jul 5;791(1-2):149-60.
Expression of a functional Fas death receptor by human foetal motoneurons. Lautrette C, Giraud S, Vermot-Desroches C, Preud’homme JL, Jauberteau MO. Neuroscience. 2003;119(2):377-85.
In vitro induction of neuronal apoptosis by anti-Fas antibody-containing sera from amyotrophic lateral sclerosis patients. Yi FH, Lautrette C, Vermot-Desroches C, Bordessoule D, Couratier P, Wijdenes J, Preud’homme JL, Jauberteau MO. J Neuroimmunol. 2000 Sep 22;109(2):211-20.

Publications de référence

The value of personalized treatment (Rx) planning (PTP): Cost savings (sav) by the Microculture Kinetic (MiCK) chemosensitivity (CS) assay, evidence from a large American self-insured company (ASIC). Latimer RG, Presant CA, Hallquist AE, Perree M, Agapitos D. Journal of Clinical Oncology, ASCO communication 2009.
Chemosensitivity testing with ChemoFx and overall survival in primary ovarian cancer. Herzog TJ, Krivak TC, Fader AN, Coleman RL. Am J Obstet Gynecol. 2010 Jul;203(1):68.e1-6.
The microculture-kinetic (MiCK) assay: the role of a drug-induced apoptosis assay in drug development and clinical care. Bosserman L1, Prendergast F, Herbst R, Fleisher M, Salom E, Strickland S, Raptis A, Hallquist A, Perree M, Rajurkar S, Karimi M, Rogers K, Davidson D, Willis C, Penalver M, Homesley H, Burrell M, Garrett A, Rutledge J, Chernick M, Presant CA. Cancer Res. 2012 Aug 15;72(16):3901-5.
Precision medicine for cancer with next-generation functional diagnostics. Friedman AA, Letai A, Fisher DE, Flaherty KT. Nat Rev Cancer. 2015 Dec;15(12):747-56.
Application of a drug-induced apoptosis assay to identify treatment strategies in recurrent or metastatic breast cancer. Bosserman L1, Rogers K2, Willis C2, Davidson D3, Whitworth P4, Karimi M1, Upadhyaya G1, Rutledge J5, Hallquist A6, Perree M6, Presant CA7. PLoS One. 2015 May 29;10(5):e0122609.
Predictive Value of Ex Vivo Chemosensitivity Assays for Individualized Cancer Chemotherapy: A Meta-Analysis. Blom K, Nygren P, Larsson R, Andersson CR. SLAS Technol. 2017 Jun;22(3):306-314. doi: 10.1177/2472630316686297.